Leukaemia & Lymphoma Research’s reaction to today’s decision by the National Institute for Health and Clinical Excellence (NICE) to recommend only one of two new chronic myeloid leukaemia (CML) drugs on the NHS:
Dr David Grant, Scientific Director at Leukaemia & Lymphoma Research, said: “We’re delighted that at least one second-line drug, nilotinib (Tasigna), will be available for those patients who either are intolerant of or become resistant to imatinib (Glivec). These drugs offer real hope and an important ‘safety net’ for patients with this cancer, which until a decade ago had a very poor prognosis.
However, nilotinib and dasatinib (Sprycel) have both been proven to be clinically effective in treating CML patients and certain patients may respond better to dasatinib. We are disappointed that NICE have not approved both drugs, which would have allowed doctors to choose the most suitable for the individual patient.”